THERAPY OF ABNORMAL UTERINE BLEEDING IN ADENOMYOSIS AND CONNECTIVE TISSUE DYSPLASIA

Abstract

Abstract: Connective tissue dysplasia (DST) is a genetically determined condition characterized by connective tissue defects, which leads to impaired development and functioning of organs and systems. At the same time, various pathological manifestations of this pathology may occur, including disorders in the reproductive system. The study of this clinical case made it possible to demonstrate the effectiveness of two-stage therapy using a surgical stage (hysteroresectoscopy, endometrial ablation, embolization of the left uterine artery) and a subsequent stage - hormonal therapy with gonadotropin-releasing hormone agonists (aGn-RG) (buserelin) for six months, followed by the introduction of levonorgestrel-containing intrauterine system Mirena in the treatment of a patient with adenomyosis and connective tissue dysplasia (DST). The disappearance of chronic pelvic pain was noted by the 3rd month of treatment. In the future, the patient's pain syndrome did not resume. During the examination of the patient twelve months after the start of treatment, positive dynamics in the treatment of adenomyosis was revealed, expressed in normalization of the size of the uterus and the structure of the myometrium, relief of pain and abnormal uterine bleeding. The indicators of blood clotting and biochemical blood analysis were within the reference values during the examination. No adverse reactions were detected during treatment. The tolerability of therapy is good. Thus, based on the study of this clinical case, it can be concluded about the effectiveness of the proposed management tactics for a patient with DST and abnormal uterine bleeding caused by adenomyosis and recommend this type of therapy in the treatment of patients with this pathology.